Why is the A2 Milk share price underperforming on Tuesday?

A broker downgrade is weighing on this infant formula company's shares.

| More on:
A young man stands facing the camera and scratching his head with the other hand held upwards wondering if he should buy Whitehaven Coal shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market may be charging higher today, but the A2 Milk Company Ltd (ASX: A2M) share price hasn't been able to follow its lead.

In afternoon trade, the infant formula company's shares are down 1.5% to $5.87.

Why is the A2 Milk share price underperforming?

The weakness in the A2 Milk share price on Tuesday has been driven by the release of a broker note out of Bell Potter this morning.

According to the note, the broker has downgraded the company's shares to a hold rating with a reduced price target of $6.80.

While this still implies decent upside from current levels, the broker doesn't appear to believe the risk/reward is compelling enough to retain its buy rating.

What did the broker say?

Bell Potter has been analysing the results and commentary from A2 Milk's dairy processing partner Synlait Milk (ASX: SM1) and seems a touch concerned with what it saw.

The broker believes that A2 Milk could now be destined to fall short of consensus estimates in the near term. It explained:

The recent SM1 downgrade was reflective of changes to existing IMF customer orders, elevated cost structures (some of which is recoverable in customer agreements) and a delayed ramp-up of the new Pokeno nutritionals customer. What the SM1 result highlighted to us, was that our nutritionals forecasts for SM1 (and hence A2M IMF demand) have been softer than consensus expectations and this is also reflected in our below consensus FY24e A2M forecasts

We downgrade from Buy to Hold. Ultimately A2M and SM1 balance dates don't align and SM1 issues may simply reflect restocking and destocking decisions on the part of A2M around SAMR registration. While we like the long-term story in A2M, we are cognisant that FY24e market expectations are higher than ours and unfortunately we saw more in the recent SM1 1H23 result to support our current forecasts than make us consider materially upgrading them.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended A2 Milk. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Broker written in white with a man drawing a yellow underline.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these stocks.

Read more »

man thinking about whether to invest in bitcoin
Broker Notes

Why now is the time to buy this beaten down $8b ASX 200 stock

Goldman Sachs thinks that now is the time to invest in this beaten down drinks giant.

Read more »

a man sits alone in his house with a dejected look on his face as he looks at a glass of red wine he is holding in his hand with an open bottle on the table in front of him.
Broker Notes

Red alert! 4 ASX All Ords shares just got broker downgrades

These ASX All Ords stocks have caught the attention of brokers for all the wrong reasons.

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Bell Potter names more of the best ASX stocks to buy

The broker has good things to say about these stocks.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Smiling man working on his laptop.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Broker Notes

These ASX shares could rise 25% to 30%

Big returns could be on offer from these stocks according to analysts.

Read more »

Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »